(Total Views: 620)
Posted On: 02/16/2021 10:36:44 PM
Post# of 72440
Great News JFM latest news feed:
________________________________________________________________________
Brilacidin getting a PUBLIC RELATIONS BOOST???...
IMO...Brilacidin will likely get a real boost from IPIX Scientific Advisor, Wm DeGrado PhD
Dr. DeGrado presents on Tuesday May 11th...1:50 pm ...at Cambridge Healthtech Institute's 23rd Annual
Dr DeGrado will be "KEYNOTE SPEAKER" for the "COMPUTATIONAL PROTEIN ENGINEERING AND DESIGN"
Display of Biologics
"Designing Antibody Drugs of the Future"
The field of biologics has relied on the engine of display technologies to produce a breadth of constructs that include bispecific antibodies, antibody-drug conjugates, immunotherapy constructs, and antibodies targeting SARS, MERS and emerging coronaviruses as well as membrane proteins with ever greater potency and target specificity. This year’s program will feature blockbuster papers that cover a range of exciting developments- don’t miss the premier event of the year.
Dr. DeGrado presents on Tuesday May 11th...1:50 pm is THE....
KEYNOTE (speaker) PRESENTATION: Computational Design of Binding Proteins (...the process usedd to develop Brilacidin)
...This talk will focus on new approaches to de novo computational design of proteins...might we hear more about his baby...BRILACIDIN???
ABOUT DR. DEGRADO:
William (Bill) DeGrado’s work focuses on the design of small molecule drugs, peptides, proteins to address biological and mechanistic questions. Since 2011, Bill has been a professor in the Department of Pharmaceutical Chemistry at the University of California San Francisco, where he is also a member of the Cardiovascular Research Institute and an adjunct member of the Institute for Neurodegenerative Diseases. Prior to UCSF, he was he was a member of DuPont Central Research and DuPont Merck Pharmaceutical Company from 1981 to 1996 and the Raiziss
1. Professor in the Department of Biochemistry and Biophysics at the University of Pennsylvania (1996 – 2011). He has served as a
2. Visiting professor or adjunct faculty at Harvard (Department of Chemistry);
3.Johns Hopkins (Biophysics),
4.University of Pennsylvania (Biochemistry & Biophysics) and UCSF (Pharmaceutical Chemistry).
Bill is also co-founder of Pliant, a company devoted to finding cures for fibrotic diseases (http://pliantrx.com). Some of Bill’s research interests include: de novo design of proteins and peptides; peptide mimetics; protein mis-folding diseases, structure/function of membrane proteins, including integrins and viral ion channels; small molecule drug design; bioinorganic chemistry.
https://www.pegsummit.com/Phage-Display#WilliamDeGrado
________________________________________________________________________
Brilacidin getting a PUBLIC RELATIONS BOOST???...
IMO...Brilacidin will likely get a real boost from IPIX Scientific Advisor, Wm DeGrado PhD
Dr. DeGrado presents on Tuesday May 11th...1:50 pm ...at Cambridge Healthtech Institute's 23rd Annual
Dr DeGrado will be "KEYNOTE SPEAKER" for the "COMPUTATIONAL PROTEIN ENGINEERING AND DESIGN"
Display of Biologics
"Designing Antibody Drugs of the Future"
The field of biologics has relied on the engine of display technologies to produce a breadth of constructs that include bispecific antibodies, antibody-drug conjugates, immunotherapy constructs, and antibodies targeting SARS, MERS and emerging coronaviruses as well as membrane proteins with ever greater potency and target specificity. This year’s program will feature blockbuster papers that cover a range of exciting developments- don’t miss the premier event of the year.
Dr. DeGrado presents on Tuesday May 11th...1:50 pm is THE....
KEYNOTE (speaker) PRESENTATION: Computational Design of Binding Proteins (...the process usedd to develop Brilacidin)
...This talk will focus on new approaches to de novo computational design of proteins...might we hear more about his baby...BRILACIDIN???
ABOUT DR. DEGRADO:
William (Bill) DeGrado’s work focuses on the design of small molecule drugs, peptides, proteins to address biological and mechanistic questions. Since 2011, Bill has been a professor in the Department of Pharmaceutical Chemistry at the University of California San Francisco, where he is also a member of the Cardiovascular Research Institute and an adjunct member of the Institute for Neurodegenerative Diseases. Prior to UCSF, he was he was a member of DuPont Central Research and DuPont Merck Pharmaceutical Company from 1981 to 1996 and the Raiziss
1. Professor in the Department of Biochemistry and Biophysics at the University of Pennsylvania (1996 – 2011). He has served as a
2. Visiting professor or adjunct faculty at Harvard (Department of Chemistry);
3.Johns Hopkins (Biophysics),
4.University of Pennsylvania (Biochemistry & Biophysics) and UCSF (Pharmaceutical Chemistry).
Bill is also co-founder of Pliant, a company devoted to finding cures for fibrotic diseases (http://pliantrx.com). Some of Bill’s research interests include: de novo design of proteins and peptides; peptide mimetics; protein mis-folding diseases, structure/function of membrane proteins, including integrins and viral ion channels; small molecule drug design; bioinorganic chemistry.
https://www.pegsummit.com/Phage-Display#WilliamDeGrado
(3)
(0)Scroll down for more posts ▼
